GSK extends vaccine partnership with Zhifei in China
Portfolio Pulse from
GSK has extended its partnership with Chongqing Zhifei Biological Products to distribute its shingles vaccine, Shingrix, in mainland China until 2034. This agreement grants Zhifei exclusive rights to import, distribute, and promote the vaccine.
December 05, 2024 | 9:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK has extended its partnership with Zhifei to distribute Shingrix in China until 2034, granting Zhifei exclusive rights to import, distribute, and promote the vaccine.
The extension of the partnership with Zhifei allows GSK to secure a long-term presence in the Chinese market for its Shingrix vaccine. This could lead to increased revenues from the Chinese market, positively impacting GSK's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100